Related references
Note: Only part of the references are listed.Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
Adrian C. Newland et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation
Elena Monzon Manzano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Reevaluation of platelet function in chronic immune thrombocytopenia: impacts of platelet size, platelet-associated anti-αIIbβ3 antibodies and thrombopoietin receptor agonists
Nobuko Nishiura et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Why do patients with immune thrombocytopenia (ITP) experience lower bleeding events despite thrombocytopenia?
Renee Boulware et al.
THROMBOSIS RESEARCH (2020)
A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia
Hanny Al-Samkari et al.
BLOOD ADVANCES (2020)
Danazol as a second-line treatment for immune thrombocytopenic purpura
Jacques Zimmer
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia
David Gomez-Almaguer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Cindy Neunert et al.
BLOOD ADVANCES (2019)
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD ADVANCES (2019)
Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment
Hung Chang et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Contributions of a regional approach to document hematologic disease in Mexico: a 10-year experience in an open population
Jose Carlos Jaime-Perez et al.
HEMATOLOGY (2018)
Emerging Concepts in Immune Thrombocytopenia
Maurice Swinkels et al.
FRONTIERS IN IMMUNOLOGY (2018)
Eltrombopag-based combination treatment for immune thrombocytopenia
David Gomez-Almaguer
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Clinical updates in adult immune thrombocytopenia
Michele P. Lambert et al.
BLOOD (2017)
Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome
Lamiae Grimaldi-Bensouda et al.
HAEMATOLOGICA (2016)
Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome
Lamiae Grimaldi-Bensouda et al.
HAEMATOLOGICA (2016)
Advances in Diagnosis and Treatments for Immune Thrombocytopenia
Shosaku Nomura
CLINICAL MEDICINE INSIGHTS-BLOOD DISORDERS (2016)
Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia
June Li et al.
NATURE COMMUNICATIONS (2015)
Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis
Katja M. J. Heitink-Polle et al.
BLOOD (2014)
Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults
David Gomez-Almaguer et al.
BLOOD (2014)
High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia
David Gomez-Almaguer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Positioning new treatments in the management of immune thrombocytopenia
Donald M. Arnold
PEDIATRIC BLOOD & CANCER (2013)
Chronic kidney disease may be differentially diagnosed from pre-eclampsia by serum biomarkers
S. Davies
ANNALS OF CLINICAL BIOCHEMISTRY (2013)
Risk and prognosis of adult primary immune thrombocytopenia
Henrik Frederiksen et al.
EXPERT REVIEW OF HEMATOLOGY (2012)
Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group
Thomas Kuehne et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production
Diane Nugent et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Francesco Zaja et al.
HAEMATOLOGICA (2008)
Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience
Maria Gabriella Mazzucconi et al.
BLOOD (2007)
The pathogenesis of immune thrombocytopaenic purpura
N Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life
JB Bussel et al.
THROMBOSIS AND HAEMOSTASIS (2004)
Medical progress: Immune thrombocytopenic purpura.
DB Cines et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
